August 2007

Dear Colleagues:
Many of you are in the midst of the summer period and I hope the season gives you renewed strength and health. We are only a few weeks away from the World Conference in Seoul, Korea and a very exciting program has been established by the local organizers and the international committee. We hope to see as many of you as possible there. During the conference there will be the IASLC Business Meeting (September 5), and many things will be discussed and voted for, among them the new bylaws for IASLC. It is our hope that as many of you as possible will be at the business meeting and make suggestions for improvement of the IASLC organization. There will also be a special workshop on design of clinical trials and translational research (see below), which should be attractive for most of the participants.
A significant achievement has been made by the IASLC staging committee, which is presenting a new international staging system of lung cancer in 5 separate publications in JTO.

Fred R. Hirsch, MD, PhD
Editor, IASLC Newsletter

IASLC and ESMO co-sponsor a biennial European Lung Cancer Conference
An agreement has been made by IASLC and ESMO to co-sponsor a biennial multidisciplinary lung cancer conference in Europe. The conference will be open for abstract presentations and will also include invited speakers in selected topics. The first conference will be held in Geneva, Switzerland, April 23-26, 2008. For further information contact .

JTO log in information
Many IASLC members have taken advantage of free full text access to Journal of Thoracic Oncology at Free access is a member benefit, but registration is now required. To register, go to, click "Register" then "Activate Account." In the "Account Number/Member ID" box type IASLC followed by your IASLC member number.
If you have registered and forgotten your user name and/or password, please contact the Wolters Kluwer Health customer service line at 800-638-3030 or 301-223-2300. The customer service rep can look up the user name/password based on an e-mail address.

IASLC Bylaws to be voted on at the coming Business meeting in Seoul, Korea – September 5, 2007
New bylaws will be voted on at the IASLC Business meeting in Seoul, Korea. The new bylaws were distributed to all the IASLC members in early June 2007. If for any reason you have not received the bylaws, please
contact the IASLC Office (

Clinical Trials and Biostatistics Workshop: Seoul, Korea – September 1, 2007
This unique workshop was designed to bring together clinicians and statisticians to discuss current problems and potential solutions to issues in the design and analysis of lung cancer clinical trials and translational science. Each of the afternoon sessions pairs an oncologist with a biostatistician (some also have a formal moderator) to present a particular issue and approach. Two evening panels explore opportunities for lung cancer trials in Asia, and different models for clinical trial conduct.
Many of the current issues arise because of the development of newer, targeted therapies. The traditional phase II endpoint of tumor shrinkage may no longer be appropriate in such settings, and there may not be good historical data on newer endpoints such as disease control rate, so new phase II and phase II/III designs are needed. In addition, the degree to which therapies are targeted (and targets can be measured) has implications for the design of phase III trials.
The ability to measure thousands of gene expression levels, gene variants or gene products brings with it the challenge of sorting through these high dimensional data sets to identify which patients will benefit from particular therapies. The goal is to use genetic characteristics of the tumor and/or the host to tailor therapy.
Finally, the hope persists that the patient’s immune system can be enhanced and used to fight cancer. This field of immunotherapy also raises particular issues of clinical trial design. For more information please contact:
1:00 – 1:30 pm: Introduction, Overview
1:30 – 2:30 pm: Phase II Trials – Endpoints
2:30 – 3:00 pm: Phase II into Phase III Trials
3:00 – 3:30 pm: Break
3:30 – 4:30 pm: Designs for targeted Therapies
4:30 – 5:00 pm: High dimensional markers
5:00 – 5:30 pm: Pharmacogenomics
5:30 - 6:00 pm: Designs for Vaccine Trials and Immunotherapy

The IASLC Lung Cancer Staging Project
New International Classification System Published in JTO
After several years of work the IASLC Staging committee is presenting a new international staging system for lung cancer. Five publications are
published in JTO this summer.
The IASLC Lung Cancer Staging project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology 2: 593-602, 2007
The IASLC Lung Cancer Staging project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology 2: 603-612, 2007.
The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology 2: 686-693, 2007.
The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and consequent stage groupings in the Forthcoming (Seventh) edition of the TNM classification of malignant Tumours. Journal of Thoracic Oncology 2: 694-705, 2007.
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. Journal Thoracic Oncology 2: 706-714, 2007.
The IASLC would like to congratulate the staging committee and the chair, Dr. Peter Goldstraw, for this significant achievement.

US Senate commits to make lung cancer research a national public health priority.
In a meeting August 2nd, 2007 the US Senate unanimously confirmed its commitment to make lung cancer research a national public health priority. The resolution calls on President Bush to declare lung cancer a public health priority and to order health agencies to develop a comprehensive coordinated program and cut lung cancer mortality in half by 2015. The areas of action includes increased funding for translational research and specialized lung cancer research centers; more action on early detection; expedited development of chemoprevention; and targeted therapies and screening pilot programs under Medicare.


Chandra Belani
Dr. Chandra Belani has per July 1st, 2007 been appointed as Deputy Director, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine. Contact Information:





The IASLC Conflict of Interest Policy
At the Board of Directors meeting June 5th, 2007 an IASLC Conflict of Interest Policy was approved and made effective. The complete document can be found on

IASLC Welcome new members:
Linda Mileshkin
Bernadette Asuncion
Michael Patrick MacManus
Michael O'Keefe
Kam M.Hui
Philip Eng
Paulo Gabbay
Pyng Lee
South Korea
S. Kishore Thain
Jung-Gi Im
Seung Bum Han
Zhenfa Zhang
Vicente Giner
Yann Le Cocguic
Philippe Girard
Oliver Gautschi
Martina Witzel
Ufuk Yilmaz
United Kingdom
Christophoros Foroulis
Tim Lewis
George Xinarianos
Judit Moldvay
Sandra Hudson
Namrata Agarwal
Mary Jo Fidler
Kate Forster
Ichiro Yoshino
Sujay Kango
Takahiro Mochizuki
Maher Tabba
Takashi Iwata
Diane Colaizzi
Ichiro Yoshino
Michael Mann
Naruyuki Kobayashi
Archana Sah
Tetsuya Mizuno
Lorriana Leard
Chiaki Endo
Drew Zepp
Toshiro Niki
Hamid Mirshahidi
Kimio Yonesaka
Hong Gwan Seo
Biao He
Carolyn Blanckmeister
Liang You
Steve Madison
Coming IASLC Workshops
November 2-4, 2007 6th Conference of the International Society for Prevention of Tobacco Induced Diseases
Place: Little Rock, Arkansas Contact: Carolyn Dresler For more information:
November 14-17, 2007 Turkish Thoracic Society Place: Istanbul, Turkey Contact: Muzaffer Metintas, MD Email:
February 21-23, 2008 8th Targeted Therapy Meeting Place: Santa Monica, CA For more information:
October 9-10, 2008 3rd Latin American Cancer Conference Place: Vina del Mar, Chile Contact: Nise Yamaguchi, MD For more information: or
April 24-26, 2008 IASLC/ESMO Lung Cancer Conference Place: Geneva, Switzerland Contact: Pia Hirsch For more information:
July 2008 International Lung Cancer Research Workshop Place: Liverpool, UK Contact: John Field For more information:
November 13-15, 2008 Chicago/IASLC/ASCO/ASTRO Malignancies of the Chest and Head and Neck Place: Chicago, Illinois For more information:
December 5-7, 2008 3rd Asia Pacific Lung Cancer Congress Place: India For more information: